The Role of Biomarkers in Drug Safety

Live webinar
Tuesday, March 21, 2017 at 12pm US PDT | 2pm CDT | 3pm EDT



The Role of Biomarkers in Drug Safety (part 2)


Tuesday, March 21, 2017


3.00 pm Eastern Daylight Time


1 hour

(If this time is not suitable for you, please register anyway and we will send you a link to the recording after the session)


Safety biomarkers offer potential benefits throughout the drug lifecycle. These range from the identification of drug candidates most likely to be tolerated in humans, through to predictive identification of patients most likely to benefit from, or not be harmed by, a treatment.

Whether you are involved in R&D, product strategy, or working directly in a drug safety related role, this webinar will provide useful insights on key learnings to date as well as exploring what the future may hold.

In this webinar you will learn:

  • The utility of safety biomarkers throughout the drug development process
  • The regulatory framework for biomarker qualification 
  • Insight into how to identify biomarker information from the literature 
  • The role of biomarkers in post-marketing pharmacovigilance practices 

This is the second in a two-part series on the topic “Pharmacovigilance and Safety Biomarkers”. You can download slides from the first part here


Kerryn Kilkenny, Content Development Manager, Adis Business Intelligence
Springer Nature

Inspired by innovation and providing value to customers, Kerryn has worked creating novel solutions for pharmaceutical companies for over 17 years. Working globally with clients in Europe, the US and Asia Pacific has provided Kerryn with insight into an array of pharmaceutical and healthcare environments and an understanding of the content and solutions available to meet different information needs.

Seth Taylor, Head of Product and Marketing

As an enterprise software entrepreneur, Seth’s career has included co-founding a recruiting software company, and Workday, a huge success in the burgeoning SaaS enterprise software space. Seth is excited to see Amplion contribute to the realization of the promise of personalized medicine. Seth writes actively on topics related to biomarkers and personalized medicine at the Biomarker Trends blog.